Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 AcquisitionLawrence Corey, Myron S. Cohen, Javier R. Lama et al.|New England Journal of Medicine|2021Cited by 540
The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trialNadine Rouphael, Wendy Nesheim, Michele Paine et al.|The Lancet|2017Cited by 423
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living FacilitiesMyron S. Cohen, Jason Morris, Ajay Nirula et al.|JAMA|2021Cited by 208
Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for DeliverySpyros A. Kalams, Scott Parker, Marnie Elizaga et al.|The Journal of Infectious Diseases|2013Cited by 197
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyLindsey R. Baden, Hong‐Van Tieu, Daniel J Stieh et al.|The Lancet HIV|2020Cited by 91